There's a new kid on the diabetes block. GlaxoSmithKline's ($GSK) albiglutide, now dubbed Tanzeum for the U.S. market, nabbed FDA approval Tuesday. Now, the drug will go up against a triad of other GLP-1 treatments, including Novo Nordisk's ($NVO) powerhouse Victoza and AstraZeneca's ($AZN) exanatide franchise. Report